| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
NDSB-201 does not have a defined pharmacological target. It is a biochemical reagent used in protein chemistry and structural biology rather than a drug substance. Its mechanism of action in protein studies involves the stabilization of protein native states by reducing protein aggregation and promoting correct folding through interactions with protein surface charges. The zwitterionic nature of the compound allows it to interact with both positively and negatively charged amino acid residues on protein surfaces, thereby preventing non-specific aggregation. It is used in the refolding of denatured proteins and in the stabilization of proteins during purification and storage.
|
|---|---|
| ln Vitro |
3-(Pyridin-1-ium-1-yl)propane-1-sulfonate is a biochemical reagent that can be utilized in studies pertaining to life sciences as an organic substance or biological material.
In vitro, NDSB-201 is used as a protein stabilization and refolding agent. It has been shown to enhance the solubility and stability of various proteins in solution, preventing aggregation and precipitation. The compound is effective at concentrations ranging from 0.1-1.0 M and is compatible with most biological assay systems. It does not interfere with enzymatic activity assays, protein-protein interaction studies, or spectroscopic measurements, making it a valuable additive for in vitro biochemical assays. NDSB-201 is also used in crystallization screens for protein crystallization, where it can promote crystal formation by reducing surface entropy and promoting ordered packing. |
| ln Vivo |
In vivo data for NDSB-201 are not available, as the compound is not intended for in vivo administration. It is a biochemical reagent used exclusively in vitro for protein chemistry applications. The compound is not designed for therapeutic use and has no established in vivo pharmacokinetic or pharmacodynamic profile. Its applications are limited to laboratory research settings for protein handling and characterization.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, NDSB-201 is not evaluated as a test compound but rather as an assay additive. Standard protocols involve the addition of NDSB-201 to assay buffers at concentrations of 0.1-1.0 M to improve protein stability and prevent aggregation during binding studies. The compound does not typically interfere with ligand-receptor binding or enzyme activity and can be used in a wide range of assay formats including ELISA, SPR, and fluorescence polarization. It is compatible with most buffer systems including Tris, HEPES, and phosphate buffers at pH 6.0-8.5.
|
| Cell Assay |
For in vitro cell-based assays, NDSB-201 is not typically used directly in cell culture due to its high ionic strength and potential osmotic effects. However, it may be used in the preparation of protein samples that are subsequently added to cell cultures. The compound's primary applications are in cell-free systems for protein characterization and structural studies. It is not intended for use in cell viability or cytotoxicity assays as a test compound.
|
| Animal Protocol |
In vivo animal studies for NDSB-201 are not applicable, as the compound is a biochemical reagent used exclusively for in vitro protein chemistry applications. No animal studies have been conducted for this compound, and it is not intended for therapeutic or diagnostic use in animals or humans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NDSB-201 are not available, as the compound is not a drug and is not administered to living organisms. The compound is highly polar and water-soluble, with expected poor membrane permeability and negligible oral bioavailability if administered. It is not designed for systemic distribution and has no therapeutic applications requiring pharmacokinetic characterization.
|
| Toxicity/Toxicokinetics |
NDSB-201 is a biochemical reagent with low toxicity when handled appropriately in the laboratory. As a zwitterionic sulfobetaine, it is generally considered to be non-toxic and non-irritating at the concentrations used in protein chemistry applications (0.1-1.0 M). The compound is not classified as hazardous under standard GHS criteria. However, standard laboratory safety practices should be followed, including the use of personal protective equipment (gloves, safety goggles, lab coat) and working in a well-ventilated area. The compound is intended for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
Structure in the first source
NDSB-201 (3-(1-Pyridinio)-1-propanesulfonate) (CAS 15471-17-7) is a research-grade biochemical reagent, not an FDA-approved pharmaceutical drug. It belongs to the class of non-detergent sulfobetaines (NDSBs) that are widely used in protein chemistry for protein solubilization, stabilization, and refolding applications. Unlike detergents, NDSB-201 does not form micelles and does not denature proteins, making it particularly useful for studying protein structure and function under native conditions. It is commonly used in protein crystallization screens, refolding of inclusion bodies, and as an additive in biophysical characterization studies. The compound is available from various chemical suppliers for laboratory research use only. No clinical trials or approved indications exist for this compound. |
| Molecular Formula |
C8H11NO3S
|
|---|---|
| Molecular Weight |
201.24
|
| Exact Mass |
201.045
|
| CAS # |
15471-17-7
|
| PubChem CID |
84929
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
280ºC
|
| Flash Point |
160ºC
|
| LogP |
-6.17
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
213
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C([H])([H])C([H])([H])[N+]1C([H])=C([H])C([H])=C([H])C=1[H])(=O)(=O)[O-]
|
| InChi Key |
REEBJQTUIJTGAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H11NO3S/c10-13(11,12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2
|
| Chemical Name |
3-pyridin-1-ium-1-ylpropane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9692 mL | 24.8460 mL | 49.6919 mL | |
| 5 mM | 0.9938 mL | 4.9692 mL | 9.9384 mL | |
| 10 mM | 0.4969 mL | 2.4846 mL | 4.9692 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
